المؤلفون: Park, H, Garrido-Laguna, I, Naing, A, Fu, S, Falchook, GS, Piha-Paul, SA, Wheler, JJ, Hong, DS, Tsimberidou, AM, Subbiah, V, Zinner, RG, Kaseb, AO, Patel, S, Fanale, MA, Velez-Bravo, VM, Meric-Bernstam, F, Kurzrock, R, Janku, F

المصدر: Oncotarget, vol 7, iss 41
Park, H; Garrido-Laguna, I; Naing, A; Fu, S; Falchook, GS; Piha-Paul, SA; et al.(2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. ONCOTARGET, 7(41), 67521-67531. doi: 10.18632/oncotarget.11750. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1dp7g79p

مصطلحات موضوعية: Sirolimus, Adult, Male, Vorinostat, Maximum Tolerated Dose, Adolescent, TOR Serine-Threonine Kinases, Oncology and Carcinogenesis, Middle Aged, phase I, Hydroxamic Acids, Histone Deacetylase Inhibitors, Young Adult, HDAC, hemic and lymphatic diseases, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, mTOR, Humans, Female, Aged

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::512319f3ff14299dfb14919f0d8072de
https://escholarship.org/uc/item/1dp7g79p

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Evens AM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA., Yu KS; Seagen Inc., Bothell, WA 98021, USA., Liu N; Seagen Inc., Bothell, WA 98021, USA., Surinach A; Genesis Research, Hoboken, NJ 07030, USA., Holmes K; Ipsos Healthcare, New York, NY 10016, USA., Flores C; Genesis Research, Hoboken, NJ 07030, USA., Fanale MA; Seagen Inc., Bothell, WA 98021, USA., Flora DR; Gryt Health, Rochester, NY 14618, USA., Parsons SK; Tufts Medical Center, Boston, MA 02111, USA.

المصدر: Future oncology (London, England) [Future Oncol] 2024 Apr; Vol. 20 (12), pp. 749-760. Date of Electronic Publication: 2023 Sep 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Hodgkin Disease*/drug therapy , Hodgkin Disease*/pathology , Physicians* , Clinical Decision-Making*, Adult ; Humans ; Neoplasm Staging ; Survival Analysis

المؤلفون: Flora DR; Research Department, Gryt Health, Rochester, New York, USA., Parsons SK; Department of Medicine and Pediatrics, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts, USA., Liu N; Health Economics and Outcomes Research, Pfizer Inc., Bothell, Washington, USA., Yu KS; Health Economics and Outcomes Research, Pfizer Inc., Bothell, Washington, USA., Holmes K; Oncology, Ipsos Healthcare, New York, New York, USA., Flores C; Genesis Research, Hoboken, New Jersey, USA., Fanale MA; Health Economics and Outcomes Research, Pfizer Inc., Bothell, Washington, USA., Surinach A; Genesis Research, Hoboken, New Jersey, USA., Byrd R; Research Department, Gryt Health, Rochester, New York, USA., Evens AM; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.

المصدر: British journal of haematology [Br J Haematol] 2024 Apr; Vol. 204 (4), pp. 1262-1270. Date of Electronic Publication: 2024 Feb 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Hodgkin Disease*/drug therapy , Hodgkin Disease*/pathology, Adult ; Humans ; Cross-Sectional Studies ; Patient Preference ; Surveys and Questionnaires

المؤلفون: Flora DR; Gryt Health, Rochester, NY, USA., Evens AM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Liu N; Seagen Inc., Bothell, WA, USA., Yu KS; Seagen Inc., Bothell, WA, USA., Byrd R; Gryt Health, Rochester, NY, USA., Fanale MA; Seagen Inc., Bothell, WA, USA., Holmes K; Ipsos Healthcare, New York, NY, USA., Flores C; Genesis Research, Hoboken, NJ, USA., Surinach A; Genesis Research, Hoboken, NJ, USA., Parsons SK; Tufts Medical Center, 800 Washington Street, Boston, MA, 02111, USA. sparsons@tuftsmedicalcenter.org.

المصدر: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2023 Nov 02; Vol. 31 (12), pp. 664. Date of Electronic Publication: 2023 Nov 02.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Caregivers* , Hodgkin Disease*/therapy, Adult ; Humans ; Female ; Middle Aged ; Male ; Quality of Life ; Cross-Sectional Studies ; Surveys and Questionnaires

المؤلفون: Burke JM; US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA., Liu N; Health Economics and Outcomes Research, Seagen Inc., Bothell, WA, USA., Yu KS; Health Economics and Outcomes Research, Seagen Inc., Bothell, WA, USA., Fanale MA; Health Economics and Outcomes Research, Seagen Inc., Bothell, WA, USA., Surinach A; Real-World Evidence Analytics, Genesis Research, Hoboken, NJ, USA., Flores C; Evidence Strategy, Genesis Research, Hoboken, NJ, USA., Lisano J; Health Economics and Outcomes Research, Seagen Inc., Bothell, WA, USA., Phillips T; Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.

المصدر: The oncologist [Oncologist] 2023 Jun 02; Vol. 28 (6), pp. 520-530.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, T-Cell, Peripheral*/drug therapy , Lymphoma, T-Cell, Peripheral*/pathology, Adult ; Male ; Humans ; Female ; Brentuximab Vedotin/therapeutic use ; Retrospective Studies ; Prednisone ; Propensity Score ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin

المؤلفون: Parsons SK; Tufts Medical Center, Boston, MA., Yu KS; Seagen Inc., Bothell, WA., Liu N; Seagen Inc., Bothell, WA., Kumar S; Ipsos Healthcare, New York, NY., Fanale MA; Seagen Inc., Bothell, WA., Holmes K; Ipsos Healthcare, New York, NY., Flores C; Genesis Research, Hoboken, NJ., Surinach A; Genesis Research, Hoboken, NJ., Flora DR; GRYT Health, Rochester, NY., Evens AM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

المصدر: JCO oncology practice [JCO Oncol Pract] 2023 Jun; Vol. 19 (6), pp. e867-e876. Date of Electronic Publication: 2023 Mar 22.

نوع المنشور: Clinical Trial; Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101758685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2688-1535 (Electronic) Linking ISSN: 26881527 NLM ISO Abbreviation: JCO Oncol Pract Subsets: MEDLINE

مواضيع طبية MeSH: Hodgkin Disease* , Oncologists* , Physicians*, Adult ; Humans ; Positron Emission Tomography Computed Tomography/methods ; Positron-Emission Tomography/methods

المؤلفون: Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org., Park H; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, Missouri., Call SG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Madwani K; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Oki Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Velez-Bravo VM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barnes TG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garrido-Laguna I; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kurzrock R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fanale MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 01; Vol. 26 (21), pp. 5579-5587. Date of Electronic Publication: 2020 Oct 14.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Everolimus/*administration & dosage , Histone Deacetylases/*genetics , Hodgkin Disease/*drug therapy , Sirolimus/*administration & dosage , TOR Serine-Threonine Kinases/*genetics , Vorinostat/*administration & dosage, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; Brentuximab Vedotin/administration & dosage ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Everolimus/adverse effects ; Female ; Hematopoietic Stem Cell Transplantation ; Histone Deacetylase Inhibitors/administration & dosage ; Histone Deacetylase Inhibitors/adverse effects ; Humans ; Male ; Middle Aged ; Recurrence ; Sirolimus/adverse effects ; Stem Cell Transplantation ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Vorinostat/adverse effects ; Young Adult

المؤلفون: Roschewski M; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD., Dunleavy K; George Washington University Cancer Center, Washington, DC., Abramson JS; Massachusetts General Hospital Cancer Center, Boston, MA., Powell BL; Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC., Link BK; University of Iowa Hospital and Clinics, Iowa City, IA., Patel P; University of Texas Southwestern, Dallas, TX., Bierman PJ; University of Nebraska Medical Center, Omaha, NE., Jagadeesh D; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Mitsuyasu RT; University of California Los Angeles Clinical AIDS Research and Education Center, Los Angeles, CA., Peace D; University of Illinois, Chicago, IL., Watson PR; Kinston Medical Specialists, Kinston, NC., Hanna WT; University of Tennessee Medical Center, Knoxville, TN., Melani C; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD., Lucas AN; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD., Steinberg SM; Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD., Pittaluga S; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD., Jaffe ES; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD., Friedberg JW; Montefiore Medical Center, Bronx, NY., Kahl BS; Washington University School of Medicine, St. Louis, MO., Little RF; Division of Cancer Therapy and Diagnosis, National Cancer Institute, Bethesda, MD., Bartlett NL; Washington University School of Medicine, St. Louis, MO., Fanale MA; MD Anderson Cancer Center, Houston, TX, and Seattle Genetics, Seattle, WA., Noy A; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Wilson WH; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Aug 01; Vol. 38 (22), pp. 2519-2529. Date of Electronic Publication: 2020 May 26.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Burkitt Lymphoma/*drug therapy, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Burkitt Lymphoma/pathology ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prednisone/administration & dosage ; Prognosis ; Risk Factors ; Rituximab/administration & dosage ; Survival Rate ; Vincristine/administration & dosage ; Young Adult